

WORLD VACCINE



CONGRESS
EUROPE

19TH ANNUAL

October 29-31, 2018

EPIC SANA Lisboa Hotel
Lisbon, Portugal

Research,
development and
strategic partnering
for the global
vaccine industry.

CO-LOCATED WITH

CREATED BY

WORLD VETERINARY
 VACCINE CONGRESS

IMMUNO ONCOLOGY
 PROFILING CONGRESS

SPARK SOMETHING
TERRAPINN 

CONFERENCE TRACKS INCLUDE

WORLD VACCINE  CONGRESS
INFLUENZA &
RESPIRATORY

WORLD VACCINE  CONGRESS
EMERGING &
RE-EMERGING

WORLD VACCINE  CONGRESS
CLINICAL
TRIALS

WORLD VACCINE  CONGRESS
BIOPROCESSING &
MANUFACTURING

WORLD VACCINE  CONGRESS
TECHNOLOGY

WORLD VACCINE  CONGRESS
ANTIMICROBIAL
RESISTANCE

WORLD VACCINE  CONGRESS
PARTNERSHIPS

#WVCEU
• terrapinn.com/WVCEU18

INFLUENZA AND RESPIRATORY

Find ways to improve development of universal influenza, RSV, MERS and Pneumococcal vaccines.

BIOPROCESSING AND MANUFACTURING

Optimize early formulation through to clinical manufacturing, by embracing new techniques and technologies.

CANCER AND IMMUNOTHERAPY

From new adjuvant technologies to novel immunotherapies, better understand the latest developments in the fast-evolving cancer landscape.

IMMUNO-ONCOLOGY PROFILING

Discuss how profiling of the immune system using high throughput technologies can aid therapeutic design and treatment strategies cancer.

PARTNERSHIPS

Hear from exciting new vaccine biotechs presenting on their pipeline as well as case studies and on how best to form public-private partnerships.

CLINICAL TRIALS

Assess how to improve your clinical trial performance, from developing novel immunological assays to creating clinical efficacy.

EMERGING AND RE-EMERGING DISEASES

Understand the opportunities for your business in reacting to global threats like malaria, dengue and Ebola.

VETERINARY

From livestock to companion, gain crucial insights into the emerging infections and new technologies changing the landscape.

ANTI MICROBIAL RESISTANCE

An entire day dedicated to AMR – how real is the threat? Find out the role of vaccines and all other factors from public health authorities, government agencies, leading vaccine manufacturers and expert physicians for a holistic response strategy

New vaccine technology is changing the whole industry

Make sure you are at the forefront of the vaccines industry. No matter where your interest lies, we have content, networking and potential partners for you.

By bringing 3 co-located conferences and 8 tracks together under one roof, you get to choose the sessions which are the most applicable to help your business plan for the future of vaccine research, development and manufacture.

Take just three days out of the office to meet over 500+ potential customers who need to find solutions to their challenges.

7

REASONS TO ATTEND

1

What's new? Hear from over **170 senior speakers** including Lord James (Jim) O'Neil, Ana Maria Henao-Restrepo (WHO), Emily Erbelding (NIH), Dr Melanie Saville (CEPI), Dr Thomas G. Evans (Vaccitech), Dr Wayne Koff (Human Vaccines Project), Ruxandra Draghia-Akli (MSD), Prof Helen McShane (Oxford University) and many more!

2

Interact with leading government and non-profit organisations like **WHO, NIH, CEPI, ZAPI-IMI, EDCTP, APHA, GALVmed, Public Health England, South African Tuberculosis Vaccine Initiative (SATVI), Finnish Public Health Institute, Jenner Institute, IFPMA** and many more.

3

Our **Scientific Advisory Board** has ensured a sensational agenda. Made up of **20 leading pioneers of the vaccine industry** your 3 days with us will be the most memorable yet.

4

Understand how to prepare for outbreaks and develop vaccines for neglected diseases from **influenza, RSV, MERS-CoV, Lassa fever, Nipah, Zika and other arboviruses** to name a few. Our dedicated One Health track also unites both veterinary and human vaccinologists together.

5

An entire day dedicated to antimicrobial resistant diseases – how real is the threat? Find out the role of vaccines and all other factors from public health authorities, government agencies, leading vaccine manufacturers and expert physicians for a holistic response strategy.

6

If you are interested in **immunotherapy vaccines, CAR T-cells, oncolytic viruses, dendritic cells, checkpoint inhibitors**, or **combinational** methods, look no further – we have an agenda packed with immuno-oncology sessions at the co-located **Immuno-Oncology Profiling World Congress**.

7

There are more **networking** opportunities, with three days' worth of content, **extended breaks, two drinks receptions and two co-located events**, you will have even more time to meet cross sector contacts with over **500 attendees**.

OUR SCIENTIFIC ADVISORY BOARD

WORLD VACCINE
CONGRESS
EUROPE

WORLD VETERINARY
VACCINE CONGRESS

IMMUNO ONCOLOGY
PROFILING CONGRESS



PROF HANNA NOHYNEK
Deputy Director
Finish Public Health



DR GREGORY A. POLAND
Director of Mayo Vaccine
Research Group
**Mayo Clinic and
Foundation**



DR ANNALIESA ANDERSON
VP Bacterial Vaccines
Pfizer



PROF HANNEKE SCHUITEMAKER
Global Head of Viral Vaccine
Discovery and Translational
Medicine in the Infectious
Disease and Vaccines
Therapeutic Area
Janssen Vaccines



PROFESSOR ALBERT OSTERHAUS
Director, Research Center
for Emerging Infections and
Zoonoses (RIZ)
**University of Veterinary
Medicine Hannover**



DR JEFFREY ALMOND
Former Vice President
Discovery Research and
Development, Sanofi and
Visiting Professor
**University of Oxford -
Oxford Vaccine Group**



DR JAN POOLMAN
Head Bacterial Vaccine
Discovery and Early
Development
Janssen



DR JERALD SADOFF
Senior Advisor
**Janssen Infectious
Diseases and Vaccines**



DR ANTU DEY
Senior Director, Research &
Development
**International AIDS Vaccine
Initiative**



DR KONRAD STRADLER
Head of R&D Vaccines
Boehringer Ingelheim



DR ROY BAYNES
Senior Vice President Global
Clinical Development and
Chief Medical Officer
MSD



DR NATHALIE GARÇON
CEO & CSO
BIOASTER



DR CYRIL GAY
Senior National Program
Leader, Office of National
Programs
USDA



DR RINO RAPPUOLI
Chief Scientist
GSK Vaccines



DR MAHESH KUMAR
Vice President, Global
Biologics Research
Zoetis



DR BERNARD VALLAT
Honorary Director General
**Office International Des
Epizooties**



DR MILES CARROLL
Deputy Director
Public Health England



DR RALF CLEMENS
SVP
GRID Rio



PROF FRED ZEPP
Medical Director
and Chairman of the
Department of Paediatrics
University Medicine Mainz



DR JORIS VANDEPUTTE
President
**IABS (International
Alliance for Biological
Standardization)**



DR LORNE A. BABIUK
Former Vice-President
University of Alberta



PROF ROMAN PRYMULA
Professor Preventive
Medicine
**Charles University in
Prague**



DR CHRISTIANE GERKE
Head of Vaccine Programs
Institut Pasteur

OPENING PLENARY SESSION				
08:30		Chair's opening remarks Dr Gregory Poland , Director, Mayo Clinic		
08:40	   	Opening discussion: Vaccine discovery and challenges in translating research into vaccine products - Covering major challenges in translational phase of bench to clinic including scale up challenges and safety for ph1 trials - Engaging stakeholders to want to push forward - Addressing the scientific roadblocks preventing more vaccines against common and neglected infectious diseases with high mortality rates - A new strategy: Can we continue to be dependent on industry for process development and advanced clinical development, especially for products destined for LMICs? Ana Maria Henao-Restrepo MD , Team Leader, Implementation Research Initiative for Vaccine Research, WHO Emily Erbeling , M.D., M.P.H., Director, Division of Microbiology and Infectious Diseases, NIAID/NIH Dr Melanie Saville , Director of Vaccine Development, CEPI Prof Jeffrey Almond , Former VP, Discovery R&D at Sanofi Pasteur & Visiting Professor at University of Oxford		
08:40	    	Expectations and reality of cancer vaccines working: The impact of combinational approaches to immunology therapies and more targeted responses - Development of novel therapies against cancer, based on vaccines, neoantigens, checkpoint inhibitors and adoptive T cell transfer - How close are these to actually treating patients? The translation of innovative therapeutic approaches into early clinical trials - Optimal methods of antigen delivery for vaccines in dendritic cells Prof Dirk Jäger , Managing Director of Medical Oncology at the German National Cancer Center, University Hospital of Heidelberg, Germany Dr Daniel Speisser , Head of Clinical Tumour Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research Center, University of Lausanne, Switzerland Dr Thomas G. Evans , CEO, Vaccitech Dr Alex Duncan , Chief Technology Officer and Head of Research, Agenus Inc Dr Laszlo Radvanyi , Senior Vice President & Senior Global Scientific Advisor, Immunology-Oncology, EMD Serono		

10:40 Morning Networking Break				
2 X INTERACTIVE ROUNDTABLES				
11:40 to 12:25 (rotation one) and 12:25 to 13:10 (rotation two). If you have not filled out the survey please choose them on the sign-up sheets located outside of the exhibition hall/or ask registration for more information. Choose two x 45 min long roundtables for these interactive discussions with like-minded peers in:				
11:40	DNA, live vectors, adjuvanted vaccines. 30 years later, are they inter changeable or is there a specific use for each? Dr Nathalie Garcon , CEO & CSO, BIOASTER	Technical and biological opportunities in the use of large animal models relative to rodent models, for human vaccine development Professor Gregers Jungersen , National Veterinary Institute, Division of Immunology & Vaccinology - Adaptive Immunology, Technical University of Denmark	Applications of CRISPR technology in new global challenges affecting livestock Dr Christine Tait-Burkard , Assistant Professor, Division Infection & Immunity, Division Genetics & Genomics, The Roslin Institute	Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?
	AMR - Vaccines can't stop it alone but what else can?	Sponsor/CRO Partnership Optimization Marc Hoffman , CMO, Celerion Bernhard Liegl , VP Global Clinical Development, Celerion - to be updated	Intradermal delivery of therapeutic vaccines - benefits and challenges Dr Kirsty V Gapp , Global Business Manager Transdermal and Microneedle Drug Delivery, 3M - to be updated	The regulators relationship with Challenge Studies; yesterday, today & tomorrow Bruno Speder , Head Clinical Regulatory Affairs, SGS Life Sciences Dr Adrian Wildfire , Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences - to be updated
	How to transform a vaccine from benchside to Ph1 Dr Christiane Gerke , Head of Vaccine Programs, Institut Pasteur	Animal component free media: What's critical? Jeremy Gillespie , Global Sales Director, Kerry Cell Nutrition - to be updated	Structural vaccinology - the impact on the next generation of vaccines	How can we better predict upcoming influenza strains while manufacturing it in time for wide spread administration?
	Vaccine characterisation and release - In-vivo vs in-vitro and the use of 3Rs (Reduction, refinement, replacement) Dr Bassam Hallis , Head of Pre-Clinical Dev & General Project Manager, National Infection Service, Public Health England	Vaccine manufacturing process development and production	New ways of "universalizing" vaccine production: The DiViNE project Dr Manuel Carrondo , IBET Olivier Kitten , Affilogic Mikkel Nisum , GSK Jonas Anders , Merck Millipore	Eyes wide open- What your sites want to tell you! Brandon Essink , MD Medical Director, Principal Investigator, Meridian Clinical Research Victor Elinoff , MD Medical Director, Regional Clinical Research

13:10 Networking Lunch & Poster Sessions				
				
14:40	CHAIR'S OPENING REMARKS	CHAIR'S OPENING REMARKS	CHAIR'S OPENING REMARKS Prof Jeroen Kortekaas , PhD, Molecular Virologist/ Group Leader, Wageningen Bioveterinary Research	CHAIR'S OPENING REMARKS Prof Jeffrey Almond , Former VP, Discovery R&D at Sanofi Pasteur & Visiting Professor, University of Oxford
	RESPIRATORY VACCINES	THERAPEUTIC & IMMUNOTHERAPY VACCINES	ONE HEALTH	HARD TO DEVELOP VACCINES
14:45	When will a universal flu vaccines be within reach? Dr Jerald Sadoff , Advisor to CEO, Janssen	Designing effective patient-specific neoantigen cancer vaccines Dr Alex Duncan , Chief Technology Officer and Head of Research, Agenus Inc	How can ZAPI act as an interface between human and veterinary vaccine development so they can learn from each other? Dr Jean-Christophe Audonnet , Senior Director, Research Strategy and Key Alliances, Bio R&D, Merial and Coordinator at ZAPI Dr Joris Vandeputte , President, International Alliance for Biological Standardization	WHO R&D blueprint update Ana Maria Henao-Restrepo MD , Team Leader, Implementation Research Initiative for Vaccine Research, WHO
15:00				Smarter vaccine designs using synthetic virus-like particle technology and structurally optimised antigens Dr Arin Ghasparian , CEO, Virometix AG
15:15	Update on the most advanced universal flu vaccine candidate - 6 completed clinical trials Dr Tamar Ben-Yedidia , CSO, BiondVax	Cancer immunotherapy: Individualized mRNA-based vaccines for the treatment of cancer Dr Matthias Miller , Senior Project Manager, BioNTech		MVA-VLP as a Plug and Play platform for development of safe and effective single dose vaccines for Emerging Infectious Diseases, Preclinical data for Zika, Ebola and Lassa as examples Dr Farshad Guirakhoo , Chief Scientific Officer, GeoVax, Inc.
15:30	Phase IIb trial of a novel influenza vaccine regimen for the over 65s Dr Sarah Gilbert , Professor of Vaccinology, University of Oxford		Tackling the problem at the source: Update on Coronaviruses Prof Albert Osterhaus , Director Research Centre for Emerging Infections & Zoonoses, University of Veterinary Medicine Hannover	New lessons from old controversies (Lyme, DTPw, Anthrax, GWS)
15:45	Influenza vaccines immunological assessment Prof Emanuele Montomolim , Chief Scientific Officer, VisMederi Srl & Full Prof. of Public Health, University of Siena	The rationale of combining biomarkers and checkpoint inhibitors with vaccines Dr Kees Melief , CSO, ISA Pharmaceuticals	Developments for Tick Borne Encephalitis vaccine Prof Roman Prymula , Professor Preventive Medicine, Charles University in Prague	Utilizing the world's leading T cell-inducing platform
16:00	Characterization of the immune response induced by plant-made influenza vaccines Senior representative, Medicago		Updates on oral vaccination strategies to protect against rabies Dr Anthony R. Fooks , Head of Wildlife Zoonoses and Vector-Borne Diseases Research Group, Animal Plant Health Agency	Intranasal adjuvanted vaccines - Inducing mucosal immunity Dr Ali Fattom , Sr VP of Vaccine Research and Development, NanoBio Corporation
16:15		Glioblastoma Immunotherapy (VBI-1901) cancer vaccine update Adam Buckley , Vice President, Business Development, VBI Vaccines	Will we get a Zika vaccine and who should it be for? (developing world, travellers or just those as a child bearing age?)	A new strategy: Latest progress on a Herpes Zoster Vaccine Dr Senyon (Teddy) Choe , Professor of Biology, University of California San Diego & Mogam Institute
			A single-dose live-attenuated Zika vaccine Pei-Yong Shi , Sealy Center for Vaccine development, University of Texas Medical Branch, Galveston, Texas, USA	Synthetic vaccines to facilitate a rapid response to newly emerging infectious diseases Dr Jeffrey Ulmer , Head Preclinical R&D, GSK Vaccines
				Using mRNA technology from universal flu to malaria vaccines Dr Frank Baehner , Area Head Prophylactic Vaccines, CureVac

19th World Vaccine Congress

Agenda Day 1



Monday 29th October 2018

16:30 Afternoon Networking Break				
17:00	RSV sessions on Ph2 RSV CDDP formulations Dr Gregory M. Glenn , MD, President, Research and Development, Novavax	Optimising combination therapies with the aim to enhance immune and clinical responses Dr Daniel Speisser , Head of Clinical Tumour Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research Center, University of Lausanne, Switzerland	Incentivizing industry to develop vaccines for neglected diseases in LMIC Dr Jeremy Salt , CSO, GALVmed	Adjuvanted vaccines can help protect immunocompromised individuals, taking the example of Shingrix Eduardo de Gomensoro , Director Global Medical Affairs, GSK Vaccines
17:15				Clinical advances in mRNA vaccines from therapeutic cancer vaccines to prophylactic vaccines
17:30	Defining the medical need and strategy of treating respiratory diseases, depending on the population	A novel allergen-encoding immunotherapeutic vaccine in the treatment of peanut allergy Professor John D. Hayball , School of Pharmacy and Medical Sciences, University of South Australia	Controlling zoonotic diseases in the developing world Dr Lorne Babiuk , Former Vice-President (Research), University of Alberta	Next generation(s) of synthetic glycoconjugate vaccines Dr Arne von Bonin , CSO, Vaxxilon AG
17:45			Progress on CMV vaccines and antibody therapies	CEPI supported vaccine development on Lassa Fever and MERS vaccine development Alexander Kort , Head of Business Processes & Quality, Themis
18:00	Chair's closing remarks of day one followed by Drinks Reception			

19th World Vaccine Congress

Agenda Day 2



Tuesday 30th October 2018

OPENING PLENARY SESSION				
08:30		Chair's opening remarks Dr Jan T Poolman , Head Bacterial Vaccine Discovery and Early Development, Janssen		
08:35		Keynote: The role of vaccines, public awareness and industry in preventing further AMR • How critical is the risk? • Vaccines can't do it alone – How can we reduce the development of drug resistance? • Increasing investment in R&D that meets global public health needs • The need for a holistic and collaborative strategy including cross species considerations Keynote speaker: Lord James (Jim) O'Neil , Honorary Professor of Economics at the University of Manchester & author of AMR review UK Followed together by keynote panel with: Dr Martin Friede , Group Lead, Transfer of Technology for Health Products, WHO Dr Todd Black , Executive Director Infectious Diseases, Head Antibacterial and Antifungal Discovery, Merck (MSD) Dr Rino Rappuoli , Chief Scientist, GSK Vaccines		
				
				
				
09:40	Short morning break followed by session tracks			
				
10:00	CHAIR'S OPENING REMARKS	CHAIR'S OPENING REMARKS	CHAIR'S OPENING REMARKS Dr Jan T Poolman , Head Bacterial Vaccine Discovery and Early Development, Janssen Dr Annaliesa Anderson , VP, CSO Bacterial Vaccines, Pfizer	CHAIR'S OPENING REMARKS David Hipkiss , CEO, Enesi Pharma
	CLINICAL DEVELOPMENT	PROMISING IMMUNOTHERAPY APPROACHES	NEW VACCINE TECHNOLOGY	FIGHTING ANTI-MICROBIAL RESISTANCE
10:05	Moving from pre-clinical to clinical Senior representative, Viroclinics	How do we overcome CAR T immunotherapy limitations to enable the treatment of more patients? Dr Phillipe Duchateau , CSO, Collectis	Spy and Snoop technologies to accelerate vaccine development Dr Mark Howarth , Professor, Protein Nanotechnology, University of Oxford	What can we do to manage AMR? MRSA, C.diff and E.coli control efforts including Abx practices Professor Mark Wilcox , Deputy-Chair, APRHA
10:20				Bridging the Global Health Gap - Viral and bacterial vaccine development at Intravacc Dr Ivo Ploemen , Business Development Manager, Intravacc
10:35	Early and late phase clinical trial design conundrums Senior representative, PRA Health Sciences	Combining innate and adaptive immunity: NK receptors for CAR T-cell Therapy Dr David Gilham , Vice President of Research & Development, Celyad	Developing vaccines with superior stability Dr Jan Jezek , CSO, Arecor Ltd	Latest advancements in production process intensification to support demand for affordable vaccines Senior representative, Batavia Biosciences
			Bad bugs overview, what are the AMR transmission patterns? Dr Trevor Lawley , Group Leader, Wellcome Sanger Institute	High-density vero cell perfusion culture in packed-bed bioreactors Dr Jörg Schwinde , Eppendorf



11:05 Morning Networking Break					
12:05	Challenges of assay validation including cell-based format Dr Bassam Hallis , Head of Pre-Clinical Dev & General Project Manager, National Infection Service, Public Health England	T-cell therapy: Assessing the clinical progress within solid tumours Senior Representative, Adaptimmune	Using baculovirus vector technologies for vaccine production	Why and how the Netherlands maintain one of the lowest AMR rates? What bugs can be stopped by vaccines and which likely are more difficult Prof Marc Bonten , Professor, Department of Medical Microbiology, UMC Utrecht	Formulation and chromatography methods: Virus-like particle processes DiViNe project - Affinity chromatography for vaccines purification Senior representative, Affilogic
	Adjuvants: Their optimal delivery and how they advance into clinical evaluation and assessment of their performance	Priming tumours for immune checkpoint blockade using oncolytic viruses Dr Adel Samson , Lead, Translational Cancer Immunotherapy Group, Leeds Institute of Cancer & Pathology, University of Leeds	The regulation of veterinary vaccine development Dr Mel Munro , Project Manager, Biologicals Regulatory Affairs, Triveritas Ltd Large animal vaccine challenge models and recombinant vaccine technology Professor S. Louise Cosby , Head of Virology Branch, Veterinary Sciences Division Agri-Food and Biosciences Institute	The role of vaccines in preventing AMR	Virus safety for viral vaccines and viral vectors Dr Anissa Boumlic-Courtade , Associate Director, Vaccine initiative, Merck Life Sciences (MilliporeSigma)
13:05	Clinical development of emerging pathogen vaccines using adenoviral vector platform technology Dr Sarah Gilbert , Professor of Vaccinology, University of Oxford	Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity Dr Peter Timmerman , Chief Scientific Officer, Pepscan Therapeutics A new immunomodulatory strategy of releasing immunosuppression in the tumour microenvironment	Yeast-based subunit marker vaccines go multivalent Dr Hanjo Hennemann , Managing Director/ CEO, VEROVACCINES GmbH	Viral vaccines RSV & influenza: The mis-use of Abx in respiratory infections Prof Hanneke Schuitemaker , Global Head of Viral Vaccine Discovery and Translational Medicine in the Infectious Disease and Vaccines Therapeutic Area, Janssen Vaccines	Designing vaccines focusing on critical quality attributes and analytical strategies Senior representative, IDT Biologika
13:35 Networking Lunch & Poster Session					
15:05	Unplanned parainfluenza virus infection on an isolation ward - A case study Dr Adrian Wildfire , Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences - Title subject to change	Hope for late-stage ovarian cancer: Development of a personalized dendritic cell vaccine Dr Lana Kandalaft , Director, Center of Experimental Therapeutics, Ludwig Cancer Research Center, University of Lausanne, Switzerland	Novel RNA particle vaccine platform for animal health applications Dr Ruud Segers , Head of Global R&D Swine Biologicals, MSD Animal Health	Reduction of otitis by pneumococcal conjugates Prof Ron Dagan , Distinguished Professor of Paediatrics and Infectious Diseases Paediatric Infectious Disease Unit Soroka, University Medical Center	A proven single-use platform to accelerate the development and production of viral vaccines Amélie Boulais Raveneau , Vaccine Platform Marketing Manager, Integrated Solutions, Sartorius Stedim Biotech



15:35	Identifying knowledge gaps and combinational approaches to gain an effective model for Pertussis Dr Dimitri A. Diavatopoulos , Department of Pediatrics/ Laboratory of Pediatric Infectious Diseases (LPID), RUMC	Synergy of DNA Vaccines with checkpoint inhibitors and Standard of Care Agents for Prostate Cancer Dr Douglas McNeel , Chief Scientific Founder and Head of M.V.I. Scientific Advisory Board, Madison Vaccines	Innovation milestones in Aqua Health; DNA vaccines Dr Lincoln Tubbs , Director, Food Animal Vaccines R&D, Elanco Animal Health	TB, A global problem: One of the biggest bacterial disease burden Prof Mark Hatherill , Professor, Director, South African Tuberculosis Vaccine Initiative (SATVI)	Platform manufacturing processes - Designing vaccines for the Global Health need? Dr Tarit Mukhopadhyay , Senior Lecturer, Department of Biochemical Engineering, University College London
	A human challenge model of Bordetella pertussis infection, for the testing of novel whooping cough vaccines Prof Robert Charles Read , Head of Academic Unit - Clinical and Experimental Sciences, Professor of Infectious Diseases, Honorary Consultant Physician to Southampton University Hospitals	Targeting IDO positive cells with IO102, an immune modulating vaccine Dr Mai-Britt Zocca , CEO & Founder, IO Biotech ApS	The importance of transboundary and emerging infectious diseases Dr Alicia Urniza , Director EU Biologicals, VMRD, Zoetis	Antibody-Antibiotic Conjugates: A novel therapeutic platform against bacterial infections	Targeted delivery in rational vaccine design Dr Dennis Christensen , Head of Vaccine Adjuvant Research grp., Dept. Infectious Disease Immunology, Statens Serum Institut
16:35	World Bank collaboration and its capacity for vaccine trials in emerging countries (strategy and plans) Dr Michael Makanga , Executive Director, European & Developing Countries Clinical Trials Partnership (EDCTP)	Improving cancer vaccine manufacturing to GMP compatible bioprocesses Dr Cristina Peixoto , Head of Downstream Process Development, IBET	Plasmid launched live attenuated virus vaccines for endemic and epizootic viral livestock diseases Dr Joeri Auwerx , Director Discovery Research, ViroVet Development and scale up of innovative vaccine production systems	E.coli vaccine development Dr Jan T Poolman , Head Bacterial Vaccine Discovery and Early Development, Janssen	Advances in intradermal drug delivery Dr Yotam Levin , CEO, NanoPass Technologies Glen Zimmermann , Senior Director Business Development, West Pharmaceutical Services
	Challenges in Phase IV studies and register based impact research Prof Hanna Nohynek , Deputy Director Finish Public Health Institute	Novel translational biomarkers to stratify patients effectively for personalized cancer immunotherapy	The future of veterinary vaccine delivery and rethinking vaccination strategies Prof Peter Mikael Helweg Heegaard , National Veterinary Institute, Division of Immunology & Vaccinology - Innate Immunology, Technical University of Denmark	S.aureus vaccine development Dr Annaliesa Anderson , VP, CSO Bacterial Vaccines, Pfizer	Finding the missing link in complete single use fermentation line
17:35 Chair's closing remarks of day one followed by Drinks Reception					



	WORLD VACCINE CONGRESS EUROPE	IMMUNO ONCOLOGY PROFILING CONGRESS	WORLD VETERINARY VACCINE CONGRESS	WORLD VACCINE CONGRESS PARTNERSHIPS	WORLD VACCINE CONGRESS BIOPROCESSING & MANUFACTURING
	CHAIR'S OPENING REMARKS	CHAIR'S OPENING REMARKS	CHAIR'S OPENING REMARKS	CHAIR'S OPENING REMARKS	CHAIR'S OPENING REMARKS
	A CASE FOR A (NEW) VACCINE <i>Where alternative treatments are used, is there a case for a vaccine against the following diseases?</i>	BEYOND PD-1 & COMBINATION STRATEGIES	ALTERNATIVES TO ANTIBIOTICS: VETERINARY VACCINES & THE MICROBIOME	BENCH-SIDE RESEARCH TO MARKET REACH	INTEGRATED BIOMANUFACTURING & SUPPLY
09:10	Pre-clinical vaccination success towards the challenge of eliciting HIV envelope glycoprotein-directed broadly neutralizing antibodies (bNAbs) Dr Richard T Wyatt , PhD Professor of Immunology, The Scripps Research Institute & Senior Director Viral Immunology IAVI Neutralizing Antibody Center, TSRI	Beyond PD-1/PD-L1: New horizons and roadblocks in cancer immunotherapy Dr Laszlo Radvanyi , Senior Vice President & Senior Global Scientific Advisor, Immuno-Oncology, EMD Serono	Looking beyond antibiotics: Time to vaccinate Dr Paul Williams , Technical Manager, MSD Animal Health	The role of emerging markets in the global supply and demand for vaccines	Influenza A and B - Rapid and Precise Antibody-Based Quantification using Sartorius' Virus Counter 3100 Dr Katherine D. Shives , CSSGB, Scientist, Sartorius Virus Analytics, Sartorius-Stedim North America
09:40	TB vaccine development efforts Professor Helen McShane , Professor of Vaccinology, Jenner Institute, Oxford University	How do we maximise the therapeutic potential of Immuno-oncology through novel combinations? Dr Maria Karasarides , Executive Director, ImmunoOncology, Regeneron Pharmaceuticals	Overcoming the factors hindering the usefulness of veterinary vaccines as alternatives to antibiotics Dr Karin Hoelzer , Senior Officer, Health Programs, Safe food and antibiotic resistance projects, The Pew Charitable Trusts	Interactive panel: External collaborative research and partnering opportunities for vaccine development Perspectives of how collaborative partnerships with not-for-profit organizations and industry can allow research and manufacturing for global reach What does each partner require to make it work? Dr Christiane Gerke , Head of Vaccine Programs, Institut Pasteur <i>More speakers to be announced shortly</i>	The plant-based Proficia™ technology: a game changer for influenza vaccine production Senior representative, Medicago
10:10	How can we create a more effective pertussis vaccine? Dr Kingston HG Mills , Professor of Experimental Immunology, School of Biochemistry and Immunology, Head Immunology, Inflammation and Infection Research Theme, Trinity Biomedical Sciences Institute	The use of genomics to enable rational design of combinatorial immunotherapy	Overcoming the challenges of commercialising the management of the microbiome Mike Salter , R&D Facilitator, AB Agri Ltd		Continuous production of influenza viruses in cell culture and use of continuous downstream processing for purification of virus particles/viral antigens Reserved for IFPMA
10:40	Morning Networking Break				
11:20	Strategies for global hepatitis C elimination – Do we need a prophylactic vaccine? Prof Michael P. Manns , M.D., Professor, Hannover Medical School and Helmholtz Center for Infection Research, Braunschweig	Antibody based combination immunotherapy Dr Alfredo Zurlo , Chief Medical Officer, Glycotope	Advancements made in veterinary bacterial vaccines	Vaccine development efforts to prevent enteric and diarrheal diseases	Comparing traditional vaccine manufacturing to mRNA vaccine manufacturing



11:50	Vaccines development against oncoviruses	Targeting the HER3 pathway using bispecific antibodies Dr Mark Throsby , EVP & Chief Scientific Officer, Merus B.V.	REGULATION Fast authorizations of vaccines for emerging diseases Dr Rosario Bullido , Head of Veterinary Immunological Medicines Assessment Unit Veterinary Medicines Department, AEMPS	Panel: Insights on how to implement new business partnership models for international collaboration among vaccine manufacturers and government ministries Investor panel: Hear how different investors decide on who and what they invest in, and why Dr Misha Petkevich , CIO, V2M* Capital LLC/V2M* Life Sciences LP Jeffrey Moore , President, MP Healthcare Venture <i>More speakers to be announced shortly</i>	Bioprocess engineering of insect cells for enhanced production of VLPs for vaccine development Dr António Roldão , Senior Researcher, Animal Cell Technology Unit, iBET
12:20	GAS vaccine efforts Prof Anne Botteaux , Molecular Bacteriology Laboratory (BACMOL), ULB	How does immunotherapy through the utility of checkpoint inhibitors, help us think about Immune Capacity?	Regulatory pathways to enable approval of new veterinary vaccines		From development to commercialization of vaccines – A case study Dr Dicky Abraham , Executive Director, Project Leadership Group, Global Vaccine and Biologics Commercialization, Merck & Co.
12:50	Afternoon Networking Lunch				
AFTERNOON PLENARY TALKS					
13:50	 Chair remarks Dr Gregory Poland , Director, Mayo Clinic				
14:00	     Status of vaccine confidence around the world - Social and political factors that can affect uptake of vaccines - How can we better educate the public the benefits of immunisation? - How can public health institutions, government and vaccine developers help with building a coherent story - AEFI surveillance and risk communication - Are we overlooking the power of social media? Prof Hanna Nohynek , Deputy Director, Finish Public Health Institute Prof Giovanna Zanoni , Assistant Director, Immunology Unit, University Hospital in Verona Italy Ruxandra Draghia-Akli , Vice President of Vaccines Public Health & Scientific Affairs, Merck (MSD) Prof Fred Zepp , Medical Director and Chairman of the Department of Paediatrics, University Medicine Mainz Prof Roman Prymula , Professor Preventive Medicine, Charles University in Prague				
14:50	 Flumist vaccine effectiveness - It's return and the real story - Questions over the effectiveness of the live attenuated vaccine - Why it lost its recommendation - The journey, investigation and trial data to rectify this Dr Helen Bright , Head, Team of Cell and Molecular Biologics, Medimmune				
15:15	   Closing plenary: The future of vaccinology: Incorporating bioinformatics, omics and structural vaccinology into vaccine design - A bottleneck for all, the ability to manage and analyze in an integrative with all the data that is generated - interpreting everything into something meaningful Dr Gregory Poland , Director, Mayo Clinic Dr Rino Rappuoli , Chief Scientist, GSK Vaccines Dr Wayne Koff , President & CEO, The Human Vaccines Project				
16:00	Chair's closing remarks and close of congress				

The 500+ attendees in 2018 are coming from

over
75% end users
300+ companies
25 countries



Biotech



Service Providers




Pharma



Government Organization



Academia / Research Institutions



Non-Profit / Charity

Big Pharma And Biotechs Who Attended In 2017 Include:

AERAS [Astellas Pharma Inc](#) Bavarian Nordic [Baxter](#) Biological E. Limited
[Boehringer Ingelheim](#) CEPI [Ceva Animal Health](#) Department of Health and Human Services [Eli Lilly and Company](#) Emergent BioSolutions [EpiVax Inc](#) FDA
[FluGen Inc](#) Genocera Biosciences [GSK Vaccines](#) Health Canada [Icahn School of Medicine at Mount Sinai](#) Immunomic Therapeutics [Indian Immunologicals Ltd](#) Inovio [Institut Pasteur](#) Janssen Infectious Diseases and Vaccines [La Jolla Infectious Disease Institute](#) Mayo Clinic and Foundation [Medicago](#) MedImmune Inc [Merck & Co.](#) Merial [Mitsubishi Tanabe Pharma Corporation](#) Moderna Therapeutics [National Cancer Institute](#) New Link Genetics [NIAID - NIH](#) Novavax [PATH](#) Pfizer [Sabin Vaccine Institute](#) Sanaria [Sanofi Pasteur](#) SutroVax, Inc [Takeda Pharmaceuticals](#) The Bill & Melinda Gates Foundation [The Human Vaccines Project](#) The Jenner Institute - University of Oxford [Valneva](#) Vaxart [VBI Vaccines Inc](#) Walter Reed Army Institute Of Research [World Health Organisation](#) Zoetis [Yisheng Biopharma](#) Bharat Biotech [Scrum Institute](#) GAVI [UNICEF](#) IAVI [Human Vaccine Project](#) CDC [HHS](#) Stanford University School of Medicine [Scripps University](#)

YOUR PROGRAM PARTICIPATION

Top sponsors have the opportunity to take part in the following way in the conference agenda.



THOUGHT LEADERSHIP PRESENTATIONS

Deliver your message as a thought leader on a chosen topic to an audience of 500 + senior vaccine stakeholders.



CASE STUDY PRESENTATIONS

Showcase one of your best customer case studies to establish awareness and visibility to a room full of prospects.



PANEL DISCUSSIONS

Join senior vaccine stakeholders on panel discussions.



ROUNDTABLES

Host a roundtable of up to 15 industry professionals around key topics.



TECHNOLOGY SHOWCASE

If you are a biotech or platform technology company, take the opportunity to present and showcase your latest work in the relevant conference agenda



EXHIBITION STANDS

Take an exhibition stand to showcase your services, products and solutions to over 500 vaccine industry decision makers



BRANDING

Promote your brand to over 500 senior vaccine executives by taking up high impact exhibition and theatre branding at the show

YOUR NETWORKING OPPORTUNITIES



ALEXANDRA
Networking manager

NETWORKING MANAGER

If you come in as a high-level sponsor, leading up to the event you will be assigned your very own Networking Manager who will be at your beck and call to help you set up meetings in advance of your arrival to the event. Your meeting schedule will be based on your desired targets on the delegate list. On-site, the Networking Manager will facilitate your meetings in a designated area.



NETWORKING DRINKS RECEPTION

It's not always about the conference sessions. Our themed evening networking drinks reception will allow you to unwind with your peers and continue conversations in good company.



SCIENTIFIC POSTERS

Share previous unpublished research with leaders in the vaccine field within the dedicated Scientific Poster area. Taking place during the lunch on day one of the congress, the Poster Session will make it possible for you to answer questions and gain feedback.



NETWORKING LUNCHES

Our extended lunch periods in the exhibition hall will provide you with ample time to network between sessions. These lunch formats allow for more opportunities for casual conversations and introductions at your booth.


Contact **Marc Rhys-Evans** now on **+44 (0)20 7827 5945** or **marc.rhys-evans@terrapinn.com** now to secure your position ○

THE EXHIBITION

Here's an overview of the floor plan.

See the website for the most up-to-date version, where there are only a few stand spaces left- so get in touch now to secure your position before it's too late!

AVAILABLE BOOKED/ RESERVED



Meeting Tables



WHO SHOULD SPONSOR:

- Contract research organizations
- Contract manufacturing
- Pharma
- Biotech
- Platform technology
- Clinical trial site/networks
- Equipment and device manufacturers
- Drug delivery providers
- Logistics/cold chain
- Safety
- Fill/finish
- Assays developers
- Immunosequencing

Stand	Company
18	3M
10	4 Clinics
17	Batavia BioSciences
13	Biological Industries
9	ExpreS2ion Biotechnologies
31	Eppendorf
25	Eurogentec
14	IDT Biologika
8	Institute for Translational Vaccinology
11	I&L
33	Kerry
32	Luminex
37	Pantec Biosolutions
20	Pathoquest
29	Pepscan Therapeutics
19	Platinum Research Network
24	Sartorius
16	SGS
39	Triskelion
38	UTMB
30	ESCO ASTER
26	Viroclinics
15	West

2018 SPONSORS AND EXHIBITORS

Gold Sponsors



Silver Sponsors



Bronze Sponsors



Networking Reception Sponsor



Showcase Sponsors



Exhibitors

